Pharmaceutical Technology Europe, Jun 1, 2010 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Jun 1, 2010
Special Feature
Tabletting: the issues facing today's manufacturers
Compressed tablets are the most popular solid dosage form and, despite having been used for many years, still offer numerous advantages.
Tablet compression: changing trends, more demands
By Jan Vogeleer
The market for tablet compression technology and the demands placed on equipment manufacturers have changed quite significantly in recent years.
Tabletting equipment: common problems and how to avoid them
By Trevor Higgins
The most common cause of equipment problems and malfunctions is misuse or improper handling and transportation, which often leads to tablet punch damage.
Granulation: evolving slowly but surely
By Guia Bertuzzi
Granulation is the most crucial step in the manufacture of solid dosage forms.
Drying: moving from batch to continuous processes
By Griet Van Vaerenbergh
The requirements of a granule drying process haven't really changed much in recent years.
Interview
Working towards greener manufacturing
PTE spoke with Dr. Peter Dunn, Global Green Chemistry Lead at Pfizer, about the changes that yield significant energy efficiencies and the strategy behind the company's green chemistry program.
Manufacturing
Assessing environmental risk of pharmaceuticals
By D.F. de Roode
An environmental risk assessment (ERA) is now required for all new pharmaceutical product marketing authorisation applications. The author outlines the steps to this procedure.
Regulation
Detecting GMP failures
By Wolfgang Schmitt
An effective quality management system will identify the root cause of non-conformances and put measures in place to ensure that they do not recur, but is the pharmaceutical industry choosing the right methods to make sure this happens?
Information Technology
Data sharing more efficient with purpose-built LIMS
By Gary Walz
A laboratory information system (LIMS) is a key tool in facilitating communication between a pharmaceutical company and its outsourcing partners; however, most LIMS require extensive customisation before they can be used in the pharmaceutical industry.
Ask the Expert
The importance of powder characterization
By Tim Freeman
How effective powder characterization can lead to better powder understanding and control.
Outsourcing Review
EU debt crisis adds uncertainty for contract services
By Jim Miller
Having barely begun recovering from the economic slump that began in 2008, the contract services industry must now face the consequences of the debt crisis in Europe, which will include reduced bio/pharmaceutical expenditure by governments.
Spotlight
German pharma's hopes and fears
By Faiz Kermani
Despite being a historically strong performer in the pharmaceutical arena, Germany is now underperforming compared with the growth of other European markets.
Talking Point
QPSHARE: a new way to share audits
By Bernd Renger
Shared audits of suppliers offer several advantages, but networking to conduct such an audit can be challenging.
News
News
When will personalised medicine deliver on its promise? and Europe's IP system trails behind the US
Editor's Comment
This is your chance to get involved
By Fedra Pavlou
Have you ever come across a new technology, process or problem in your profession and wanted to tell others or learn more about it?

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here